The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.
Related to this article
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Choueiri on the Phase 3 LITESPARK-022 Trial of Belzutifan Plus Pembrolizumab in ccRCC
2
Bexobrutideg Aims to Overcome Resistance Mutations in R/R CLL
3
Adjuvant Immunotherapy, Risk Stratification, and Multidisciplinary Care Redefine CSCC Management
4
BPM31510 Plus Chemoradiation Drives Encouraging OS Trend in Newly Diagnosed Glioblastoma
5